Список литературы

1. Smith HO, Berwick M, Verschraegen CF et al. Incidence and survival rates forfemale malignant germ cell tumors. Obstet Gynecol 2006; 107(5): 1075 - 1085.

2. Трякин А.А., Федянин М.Ю., Буланов А.А., с соавт. Метастазы герминогенных опухолей в головной мозг. Опыт Российского онкологического центра. Онкоурология, 2013 (4): с. 59 - 71.

3. А.А. Трякин. Лекарственное и комбинированное лечение несеминомных герминогенных опухолей у мужчин. Диссертация... доктора медицинских наук: 14.00.12.; [Место защиты: ФГБУ "РОНЦ им. Н.Н. Блохина" МЗ РФ] - Москва, 2015. - 254 с.

4. Трякин А.А., Гладков О.А., Матвеев В.Б. с соавт. Практические рекомендации по лекарственному лечению герминогенных опухолей яичка. Злокачественные опухоли. - 2016. - N 4, спецвыпуск 2, - С. 353 - 366.

5. Feldman DR, Lorch A, Kramar A, et al. Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group. J Clin Oncol. 2016 Feb 1; 34(4): 345-51.

6. J. Oldenburg, S. D. Fossa, J. Nuver, et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 24 (Supplement 6): vi125 - vi132, 2013.

7. De Santis M, Becherer A, Bokemeyer C et al. 2-18Fluoro-deoxy-d-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22: 1034 - 1039.

8. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer. J Clin Oncol, 2000, 18, (12): 2413 - 2418.

9. Mead GM, Cullen MH, Huddart R, et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 2005; 93: 178 - 184.

10. P.J. Loehrer, R. Gonin, C.R. Nichols, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol, 16 (1998), pp. 2500 - 2504.

11. Sharpe RM, Skakkebaek NE. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet 1993, 341: 1392 - 1395.

12. Garner, M.J., Turner, M.C., Ghadirian, P. & Krewski, D. Epidemiology of testicular cancer: an overview. [book auth.]. Int. J. Cancer (2005) 116 331 - 339.

13. Chieffi P, Franco R, Portella G. Molecular and cell biology of testiculargerm cell tumors. Int Rev Cell Mol Biol 2009; 278: 277 - 308.

14. Hemminki K, Chen B. Familial risks in testicular cancer as aetiological clues. Int J Androl. 2006 Feb; 29(1): 205-10.

15. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr; 49(6): 1374-403.

16. International Germ Cell Collaborative Group. International Germ Cell Consensus Classification: A prognostic Factor-Based Staging System for Metastatic Germ Cell Cancers. J. Clin Oncol, 1997, 15: pp 594 - 603.

17. C. Kollmannsberger, T. Tandstad, P. Bedard, et al. Characterization of relapse in patients with clinical stage I (CSI) nonseminoma (NS-TC) managed with active surveillance (AS): A large multicenter study. J Clin Oncol 31, 2013 (suppl; abstr 4503).

18. Tandstad T., Cavallin-Stahl E., Dahl O, et al. One course of adjuvant BEP in clinical stage I, nonseminoma: Mature and expanded results from the SWENOTECA group. J Clin Oncol 31, 2013 (suppl; abstr 4553).

19. Harland SJ, Cook PA, Fossa SD, et al. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol. 1998 Oct; 160(4): 1353-7.

20. Albers, P. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I NSGCT: AUO trial AH 01/94 by the German Testicular Cancer Study. J Clin Oncol. - 2008. - 26(18). - P. 2966-72.

21. de Wit, R, J.T. Roberts, P.M. Wilkinson et al. Equivalence of Three or Four Cycles of Bleomycin, Etoposide, and Cisplatin Chemotherapy and of a 3- or 5-Day Schedule in Good-Prognosis Germ Cell Cancer: A randomized trial of EORTC and MRC/.//J Clin Oncol. - 2001. - P. 1629 - 1640.